Our Mission

Proven Solutions ImprovedSM

Tosk’s mission is to alleviate the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes.

Read more

Patented Products

Tosk has patented two new pharmaceutical products and has two other research-stage products in development. The most advanced, TK-90 for mucositis side effect reduction, has recently entered clinical studies in cancer patients. Mucositis is caused by several different cancer therapies that can damage the inner lining of the gastrointestinal tract resulting in painful ulcers and increased risk of infection.


Read more

There were 1.7 million new cases of cancer and 600,000 cancer-related deaths in the U. S. last year. This is despite regular media reports of breakthroughs in treatment, such as monoclonal antibodies and immunotherapies, and many billions of dollars spent on cancer research. New approaches may have long-term promise, but the reality is, most cancers are still treated with drugs that are decades old.

Future Drugs

Tosk has two additional drug discovery efforts. Consistent with its motto Proven Solutions ImprovedSM. Both are undergoing lead optimization, the process by which a candidate compound is modified to make it into an effective drug.


Read more

Meet Our R&D Pros

The two scientists leading Tosk’s efforts to change the fundamental nature of cancer care were inspired to pursue science in one case by his dad, in another case, by his grandfather.


Read more

Heading

Our Mission

Proven Solutions ImprovedSM

Tosk’s mission is to alleviate the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes.

Read more

center

no-repeat;center top;;

auto

Heading + desc

no-repeat;center top;;

auto

The Tosk Challenge:

Improve the quality of life and outcomes for cancer patients by reducing or eliminating the adverse side effects of therapy and making therapies available to patients who do not currently benefit.

no-repeat;center top;;

auto

50px 20px 0px 20px

Heading

Patented Products

Tosk has patented two new pharmaceutical products and has two other research-stage products in development. The most advanced, TK-90 for mucositis side effect reduction, has recently entered clinical studies in cancer patients. Mucositis is caused by several different cancer therapies that can damage the inner lining of the gastrointestinal tract resulting in painful ulcers and increased risk of infection.


Read more

center

rgba(240,240,240,0.8)

no-repeat;center top;;

auto

20px 20px 20px 20px

vclass

Transforming
Treatment



Read more

no-repeat;center top;;

auto

There were 1.7 million new cases of cancer and 600,000 cancer-related deaths in the U. S. last year. This is despite regular media reports of breakthroughs in treatment, such as monoclonal antibodies and immunotherapies, and many billions of dollars spent on cancer research. New approaches may have long-term promise, but the reality is, most cancers are still treated with drugs that are decades old.

no-repeat;center top;;

auto

Future Drugs

Tosk has two additional drug discovery efforts. Consistent with its motto Proven Solutions ImprovedSM. Both are undergoing lead optimization, the process by which a candidate compound is modified to make it into an effective drug.


Read more

left

no-repeat;center top;;

auto

no-repeat;center top;;

auto

Meet Our R&D Pros

The two scientists leading Tosk’s efforts to change the fundamental nature of cancer care were inspired to pursue science in one case by his dad, in another case, by his grandfather.


Read more

left

no-repeat;center top;;

auto

Heading

Tosk is a clinical stage oncology drug discovery and development company dedicated to improving outcomes for cancer patients by developing new drugs to block the ad-verse side effects of commonly used cancer therapies and to make certain drugs effec-tive in patients who do not currently benefit from treatment.

center

no-repeat;center top;;

auto

Heading

Patented Products

TOSK’s mission is to improve outcomes for cancer patients by enhancing the safety and efficacy of widely-used chemotherapies and radiation treatments. Our strategy is to develop a family of Companion™ drugs that reduce the toxic side effects of existing therapies. We also are working on a class of human cancer genes called oncogenic kRAS that renders certain cancer drugs ineffective in up to 40 percent of cancer patients.

“Our goal is to use our proprietary technology to discover drugs that correct this problem.”


Read more

left

rgba(240,240,240,0.8)

no-repeat;center top;;

auto

20px 20px 20px 20px

vclass

700

400

Heading + desc

ABOUT US



Read more

center

no-repeat;center top;;

auto

zoomIn

Proven Solutions ImprovedSM

TOSK’s mission is to improve outcomes for cancer patients by enhancing the safety and efficacy of widely-used chemotherapies and radiation treatments. Our strategy is to develop a family of Companion™ drugs that reduce the toxic side effects of existing therapies. We also are working on a class of human cancer genes called oncogenic kRAS that renders certain cancer drugs ineffective in up to 40 percent of cancer patients. Our goal is to use our proprietary technology to discover drugs that correct this problem.

Tosk’s drugs not only can improve the effectiveness of existing drugs, but also reduce the cost of cancer care by eliminating the need to treat painful, life-threatening side ef-fects as wells costly end-of-life therapies.

Our mission inspires a dedicated staff that is among the most experienced in the indus-try, led by biotech veterans who have founded a number of successful medical products companies. The group includes highly respected research VPs with more than 20 years of industry experience each, who guide the Company’s drug development efforts using proprietary discovery technologies.

no-repeat;center top;;

auto

Transforming
Treatment



Read more

no-repeat;center top;;

auto

There were 1.7 million new cases of cancer and 600,000 cancer-related deaths in the U. S. last year. This is despite regular media reports of breakthroughs in treatment, such as monoclonal antibodies and immunotherapies, and many billions of dollars spent on cancer research. New approaches may have long-term promise, but the reality is, most cancers are still treated with drugs that are decades old.

no-repeat;center top;;

auto

Tosk Technology

Tosk uses two proprietary drug discovery methods to identify potential CompanionTM drugs. Together, we call these methods OMDSM for Optimizing Marketed DrugsSM be-cause they allow us to efficiently screen compounds for their potential to block the ad-verse side effects of prescription drugs, or make certain drugs effective in patients who currently do not benefit from therapy.


Read more

center

no-repeat;center top;;

auto